글로벌 방사성 의약품 시장 (2023-2032) : 테크네튬 99m, 불소 18, 요오드 I, 갈륨 68, 기타

■ 영문 제목 : Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Allied Market Research가 발행한 조사보고서이며, 코드는 ALD23SEP124 입니다.■ 상품코드 : ALD23SEP124
■ 조사/발행회사 : Allied Market Research
■ 발행일 : 2023년 4월
■ 페이지수 : 300
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일
■ 조사대상 지역 : 세계
■ 판매가격 / 옵션 (부가세 10% 별도)
Single UserUSD5,730 ⇒환산₩7,735,500견적의뢰/주문/질문
5 UserUSD6,450 ⇒환산₩8,707,500견적의뢰/주문/질문
Enterprise UserUSD9,600 ⇒환산₩12,960,000견적의뢰/구입/질문
가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
글로벌 방사성 의약품 시장은 2022년 52억 달러 규모였으며, 2023년부터 2032년까지 연평균 10.2% 성장하여 2032년에는 137억 달러에 달할 것으로 예상됩니다. 방사성 의약품은 광범위한 질병을 모니터링, 진단 및 치료하는 데 사용되는 방사성 의약품으로 정의됩니다. 방사성 의약품은 치료 및 진단 목적으로 널리 사용됩니다. 치료적 적용에서 방사성 의약품은 적절한 치료 용량의 방사선이 특정 질병 부위에 전달되도록 일정량 투여됩니다. 한편 진단 절차에서는 장기의 기능을 관찰하기 위해 신체가 소량의 방사선에 노출됩니다. 방사성 의약품은 반감기가 짧기 때문에 제조 후 즉시 환자에게 투여해야 합니다.
방사성 의약품 시장은 암, 신경계 질환, 심혈관 질환과 같은 대상 질환의 유병률 증가와 의료 영상에서의 방사성 의약품 사용 증가에 의해 주도되고 있습니다. 세계 암 연구 기금 국제본부에 따르면 2020년에 전 세계적으로 약 1,810만 건의 새로운 암이 진단된 것으로 보고되었습니다. 방사성 의약품은 방사성 물질을 사용하여 암을 진단하고 치료합니다. 암 진단에 사용되는 방사성 의약품으로는 악수민, 필라리파이, 세리아나, 로카메츠, 림포시크 등이 있습니다. 또한 연구진은 방사선 치료를 세포에 직접적으로 전달하여 세포를 파괴할 수 있도록 설계된 새로운 방사성 의약품 제제를 개발하는 것을 목표로 하고 있습니다. 방사선 치료에 대한 수요가 급증하고 암 및 기타 표적 질병에 대한 진단 절차의 수가 증가함에 따라 시장의 성장이 촉진됩니다.

또한, 방사성 의약품은 생물학적 조직의 검사를 지원하기 위해 양전자 방출 단층 촬영 (PET) 이미징 중에 사용됩니다. 전립선, 심장 및 아밀로이드 이미징의 수가 증가함에 따라 PET 절차에 대한 필요성이 급증했습니다. 의료 영상에 대한 수요 증가, 방사성 의약품의 필요성 급증 및 방사성 의약품 시장의 성장 촉진 방사성 의약품에 대한 제품 승인 수의 증가는 시장의 성장을 촉진합니다.

예를 들어, 2023년 3월 생명 공학 회사인 Telix Pharmaceuticals는 미국 식품의 약국 (FDA)이 Illuccix에 대한 승인을 발표했습니다. 방사성 진단 에이전트를 형성하는 Ga 68의 방사성 표지입니다. 전립선암 환자의 전립선 특이 막 항원(PSMA) 양성 병변의 양전자방출단층촬영(PET)에 사용할 수 있다. 또한 2022년 3월 미국 식품의약국(FDA)은 성인 전립선암 환자 치료제로 플루빅토를 승인했다고 발표했습니다. 플루빅토는 최초의 PSMA 표적 방사성 의약품으로 방사성동위원소인 루테튬 루 177 비피보타이드 테트라탁스탄을 함유하고 있습니다.

또한, 헬스케어 산업의 R&D 활동이 증가하면서 시장의 성장을 촉진하고 있습니다. 코임브라 대학의 핵 과학 응용 보건 연구소는 진단 방사성 의약품 적용에 대한 현재와 미래의 수요를 충족시키기 위해 적극적으로 연구 활동에 참여하고 있습니다. 또한 방사성 의약품에 대한 임상 시험의 수가 증가함에 따라 방사성 의약품 시장의 성장이 촉진됩니다. 또한 의료 분야의 R&D 활동에 대한 투자 증가는 시장 성장을 더욱 촉진합니다. 그러나 시장 성장을 저해하는 요인으로는 메스꺼움, 구토, 복통 및 요통과 같은 방사성 의약품 사용과 관련된 부작용이 있습니다.
반면에 방사성 의약품 산업의 존재, 방사성 의약품에 대한 연구 개발 활동의 증가 및 신흥 시장의 성장 잠재력은 예측 기간 동안 방사성 의약품에 대한 막대한 기회를 창출 할 것으로 예상됩니다.

방사성 의약품 시장은 방사성 동위 원소, 응용 분야, 유형, 최종 용도 및 지역을 기준으로 세분화됩니다. 방사성 동위 원소를 기준으로 시장은 테크네튬 -99m, 플루오린 -18, 요오드 I, 갈륨 -68 등으로 분류됩니다. 기타에는 인듐-111, 이트륨-90, 루테튬 루-177, 구리-64, 탄소-14, 탄소-11, 스트론튬-89, 루비듐-82, 라듐-223, 질소-13, 몰리브덴, 갈륨-67, 탈륨-201 및 제논-133이 포함됩니다. 응용 분야에 따라 시장은 암, 심장학 및 기타로 나뉩니다. 유형에 따라 시장은 진단 및 치료제로 나뉩니다. 최종 용도를 기준으로 시장은 병원 및 클리닉, 의료 영상 센터 및 기타로 분류됩니다. 기타 부문에는 진단 센터 및 연구 기관이 포함됩니다.
지역을 기준으로 시장은 북미 (미국, 캐나다 및 멕시코), 유럽 (독일, 영국, 프랑스, 스페인, 이탈리아 및 기타 유럽 지역), 아시아 태평양 (인도, 중국, 호주, 일본, 한국 및 기타 아시아 태평양) 및 중남미/중동/아프리카 (브라질, 사우디 아라비아, 남아프리카 및 기타 중남미/중동/아프리카)에서 연구되며 글로벌 방사성 의약품 시장에서 운영되는 주요 주요 업체는 Cardinal Health Inc., Curium Pharma, Eli Lilly and Company, General Electric Company, Iso-Tex Diagnostics, Inc., Jubilant Pharmova Limited, Lantheus Holdings, Inc., Novartis AG, Siemens AG, and Bayer. 등이 있습니다.

이해관계자를 위한 주요 이점
이 보고서는 2022년부터 2032년까지 방사성 의약품 시장 분석의 시장 부문, 현재 동향, 추정치 및 역학에 대한 정량적 분석을 제공하여 일반적인 방사성 의약품 시장 기회를 식별합니다.
시장 조사는 주요 동인, 제약 및 기회와 관련된 정보와 함께 제공됩니다.
포터의 다섯 가지 경쟁 요인 분석은 이해 관계자가 이익 지향적인 비즈니스 결정을 내리고 공급 업체-구매자 네트워크를 강화할 수 있도록 구매자와 공급 업체의 잠재력을 강조합니다.
방사성 의약품 시장 세분화에 대한 심층 분석은 지배적인 시장 기회를 결정하는 데 도움이 됩니다.
각 지역의 주요 국가는 글로벌 시장에 대한 매출 기여도에 따라 매핑됩니다.
시장 플레이어 포지셔닝은 벤치마킹을 용이하게하고 시장 플레이어의 현재 위치에 대한 명확한 이해를 제공합니다.
이 보고서에는 지역 및 글로벌 방사성 의약품 시장 동향, 주요 업체, 시장 세그먼트, 응용 분야 및 시장 성장 전략에 대한 분석이 포함되어 있습니다.

주요 시장 부문
최종 용도별
병원 및 클리닉
의료 영상 센터
기타

방사성 동위원소별
요오드 I
갈륨 68
기타
테크네튬 99m
불소 18

용도별

심장학
기타

유형별
진단
치료

지역별
북미
미국
캐나다
멕시코
유럽
독일
프랑스
영국
이탈리아
스페인
기타 유럽 지역
아시아 태평양
일본
중국
호주
인도
한국
기타 아시아 태평양 지역
중남미/중동/아프리카
브라질
사우디 아라비아
남아프리카 공화국
기타 중동 및 아프리카 지역

주요 기업
○ Bayer AG
○ Cardinal Health Inc.
○ Curium Pharma
○ Eli Lilly and Company
○ General Electric Company
○ Iso-Tex Diagnostics, Inc
○ Jubilant Pharmova Limited
○ Lantheus Holdings, Inc.
○ Novartis AG
○ Siemens AG
■ 보고서 개요

CHAPTER 1 : 소개
CHAPTER 2 : 개요
CHAPTER 3 : 시장 동향
CHAPTER 4 : 방사성 의약품 시장, 방사성 동위원소별
CHAPTER 5 : 방사성 의약품 시장, 용도별
CHAPTER 6 : 방사성 의약품 시장, 유형별
CHAPTER 7 : 방사성 의약품 시장, 최종 용도별
CHAPTER 8 : 방사성 의약품 시장, 지역별
CHAPTER 9 : 경쟁 현황
CHAPTER 10 : 기업 정보

■ 보고서 목차

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of cancer, cardiovascular and neurological disease
3.4.1.2. Increase in demand for medical imaging
3.4.1.3. Increase in number of product approval for radiopharmaceuticals

3.4.2. Restraints
3.4.2.1. Side effect associated with radiopharmaceuticals

3.4.3. Opportunities
3.4.3.1. Presence of radiopharmaceutical industry
3.4.3.2. Increase in R&D activities for radiopharmaceuticals

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Technetium 99m
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Fluorine 18
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Iodine I
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Gallium 68
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Others
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: RADIOPHARMACEUTICALS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Cancer
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Cardiology
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: RADIOPHARMACEUTICALS MARKET, BY TYPE
6.1. Overview
6.1.1. Market size and forecast
6.2. Diagnostic
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Therapeutic
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: RADIOPHARMACEUTICALS MARKET, BY END USER
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospitals and clinics
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Medical Imaging centers
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Others
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: RADIOPHARMACEUTICALS MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key trends and opportunities
8.2.2. Market size and forecast, by Radioisotope
8.2.3. Market size and forecast, by Application
8.2.4. Market size and forecast, by Type
8.2.5. Market size and forecast, by End User
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Key market trends, growth factors and opportunities
8.2.6.1.2. Market size and forecast, by Radioisotope
8.2.6.1.3. Market size and forecast, by Application
8.2.6.1.4. Market size and forecast, by Type
8.2.6.1.5. Market size and forecast, by End User
8.2.6.2. Canada
8.2.6.2.1. Key market trends, growth factors and opportunities
8.2.6.2.2. Market size and forecast, by Radioisotope
8.2.6.2.3. Market size and forecast, by Application
8.2.6.2.4. Market size and forecast, by Type
8.2.6.2.5. Market size and forecast, by End User
8.2.6.3. Mexico
8.2.6.3.1. Key market trends, growth factors and opportunities
8.2.6.3.2. Market size and forecast, by Radioisotope
8.2.6.3.3. Market size and forecast, by Application
8.2.6.3.4. Market size and forecast, by Type
8.2.6.3.5. Market size and forecast, by End User
8.3. Europe
8.3.1. Key trends and opportunities
8.3.2. Market size and forecast, by Radioisotope
8.3.3. Market size and forecast, by Application
8.3.4. Market size and forecast, by Type
8.3.5. Market size and forecast, by End User
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Key market trends, growth factors and opportunities
8.3.6.1.2. Market size and forecast, by Radioisotope
8.3.6.1.3. Market size and forecast, by Application
8.3.6.1.4. Market size and forecast, by Type
8.3.6.1.5. Market size and forecast, by End User
8.3.6.2. France
8.3.6.2.1. Key market trends, growth factors and opportunities
8.3.6.2.2. Market size and forecast, by Radioisotope
8.3.6.2.3. Market size and forecast, by Application
8.3.6.2.4. Market size and forecast, by Type
8.3.6.2.5. Market size and forecast, by End User
8.3.6.3. UK
8.3.6.3.1. Key market trends, growth factors and opportunities
8.3.6.3.2. Market size and forecast, by Radioisotope
8.3.6.3.3. Market size and forecast, by Application
8.3.6.3.4. Market size and forecast, by Type
8.3.6.3.5. Market size and forecast, by End User
8.3.6.4. Italy
8.3.6.4.1. Key market trends, growth factors and opportunities
8.3.6.4.2. Market size and forecast, by Radioisotope
8.3.6.4.3. Market size and forecast, by Application
8.3.6.4.4. Market size and forecast, by Type
8.3.6.4.5. Market size and forecast, by End User
8.3.6.5. Spain
8.3.6.5.1. Key market trends, growth factors and opportunities
8.3.6.5.2. Market size and forecast, by Radioisotope
8.3.6.5.3. Market size and forecast, by Application
8.3.6.5.4. Market size and forecast, by Type
8.3.6.5.5. Market size and forecast, by End User
8.3.6.6. Rest of Europe
8.3.6.6.1. Key market trends, growth factors and opportunities
8.3.6.6.2. Market size and forecast, by Radioisotope
8.3.6.6.3. Market size and forecast, by Application
8.3.6.6.4. Market size and forecast, by Type
8.3.6.6.5. Market size and forecast, by End User
8.4. Asia-Pacific
8.4.1. Key trends and opportunities
8.4.2. Market size and forecast, by Radioisotope
8.4.3. Market size and forecast, by Application
8.4.4. Market size and forecast, by Type
8.4.5. Market size and forecast, by End User
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Key market trends, growth factors and opportunities
8.4.6.1.2. Market size and forecast, by Radioisotope
8.4.6.1.3. Market size and forecast, by Application
8.4.6.1.4. Market size and forecast, by Type
8.4.6.1.5. Market size and forecast, by End User
8.4.6.2. China
8.4.6.2.1. Key market trends, growth factors and opportunities
8.4.6.2.2. Market size and forecast, by Radioisotope
8.4.6.2.3. Market size and forecast, by Application
8.4.6.2.4. Market size and forecast, by Type
8.4.6.2.5. Market size and forecast, by End User
8.4.6.3. Australia
8.4.6.3.1. Key market trends, growth factors and opportunities
8.4.6.3.2. Market size and forecast, by Radioisotope
8.4.6.3.3. Market size and forecast, by Application
8.4.6.3.4. Market size and forecast, by Type
8.4.6.3.5. Market size and forecast, by End User
8.4.6.4. India
8.4.6.4.1. Key market trends, growth factors and opportunities
8.4.6.4.2. Market size and forecast, by Radioisotope
8.4.6.4.3. Market size and forecast, by Application
8.4.6.4.4. Market size and forecast, by Type
8.4.6.4.5. Market size and forecast, by End User
8.4.6.5. South Korea
8.4.6.5.1. Key market trends, growth factors and opportunities
8.4.6.5.2. Market size and forecast, by Radioisotope
8.4.6.5.3. Market size and forecast, by Application
8.4.6.5.4. Market size and forecast, by Type
8.4.6.5.5. Market size and forecast, by End User
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Key market trends, growth factors and opportunities
8.4.6.6.2. Market size and forecast, by Radioisotope
8.4.6.6.3. Market size and forecast, by Application
8.4.6.6.4. Market size and forecast, by Type
8.4.6.6.5. Market size and forecast, by End User
8.5. LAMEA
8.5.1. Key trends and opportunities
8.5.2. Market size and forecast, by Radioisotope
8.5.3. Market size and forecast, by Application
8.5.4. Market size and forecast, by Type
8.5.5. Market size and forecast, by End User
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Key market trends, growth factors and opportunities
8.5.6.1.2. Market size and forecast, by Radioisotope
8.5.6.1.3. Market size and forecast, by Application
8.5.6.1.4. Market size and forecast, by Type
8.5.6.1.5. Market size and forecast, by End User
8.5.6.2. Saudi Arabia
8.5.6.2.1. Key market trends, growth factors and opportunities
8.5.6.2.2. Market size and forecast, by Radioisotope
8.5.6.2.3. Market size and forecast, by Application
8.5.6.2.4. Market size and forecast, by Type
8.5.6.2.5. Market size and forecast, by End User
8.5.6.3. South Africa
8.5.6.3.1. Key market trends, growth factors and opportunities
8.5.6.3.2. Market size and forecast, by Radioisotope
8.5.6.3.3. Market size and forecast, by Application
8.5.6.3.4. Market size and forecast, by Type
8.5.6.3.5. Market size and forecast, by End User
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Key market trends, growth factors and opportunities
8.5.6.4.2. Market size and forecast, by Radioisotope
8.5.6.4.3. Market size and forecast, by Application
8.5.6.4.4. Market size and forecast, by Type
8.5.6.4.5. Market size and forecast, by End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Curium Pharma
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Key strategic moves and developments
10.2. Cardinal Health Inc.
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. General Electric Company
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.3.7. Key strategic moves and developments
10.4. Iso-Tex Diagnostics, Inc
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.5. Lantheus Holdings, Inc.
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.5.7. Key strategic moves and developments
10.6. Siemens AG
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. Jubilant Pharmova Limited
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.7.7. Key strategic moves and developments
10.8. Novartis AG
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.8.7. Key strategic moves and developments
10.9. Bayer AG
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.10. Eli Lilly and Company
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Business performance
10.10.7. Key strategic moves and developments

LIST OF TABLES
TABLE 01. GLOBAL RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 02. RADIOPHARMACEUTICALS MARKET FOR TECHNETIUM 99M, BY REGION, 2022-2032 ($MILLION)
TABLE 03. RADIOPHARMACEUTICALS MARKET FOR FLUORINE 18, BY REGION, 2022-2032 ($MILLION)
TABLE 04. RADIOPHARMACEUTICALS MARKET FOR IODINE I, BY REGION, 2022-2032 ($MILLION)
TABLE 05. RADIOPHARMACEUTICALS MARKET FOR GALLIUM 68, BY REGION, 2022-2032 ($MILLION)
TABLE 06. RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 08. RADIOPHARMACEUTICALS MARKET FOR CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 09. RADIOPHARMACEUTICALS MARKET FOR CARDIOLOGY, BY REGION, 2022-2032 ($MILLION)
TABLE 10. RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 12. RADIOPHARMACEUTICALS MARKET FOR DIAGNOSTIC, BY REGION, 2022-2032 ($MILLION)
TABLE 13. RADIOPHARMACEUTICALS MARKET FOR THERAPEUTIC, BY REGION, 2022-2032 ($MILLION)
TABLE 14. GLOBAL RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 15. RADIOPHARMACEUTICALS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($MILLION)
TABLE 16. RADIOPHARMACEUTICALS MARKET FOR MEDICAL IMAGING CENTERS, BY REGION, 2022-2032 ($MILLION)
TABLE 17. RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 18. RADIOPHARMACEUTICALS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 21. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 22. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 23. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 24. U.S. RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 25. U.S. RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 26. U.S. RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 27. U.S. RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 28. CANADA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 29. CANADA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 30. CANADA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 31. CANADA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 32. MEXICO RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 33. MEXICO RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 34. MEXICO RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 35. MEXICO RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 36. EUROPE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 37. EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 38. EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 39. EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 40. EUROPE RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 41. GERMANY RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 42. GERMANY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 43. GERMANY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 44. GERMANY RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 45. FRANCE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 46. FRANCE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 47. FRANCE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 48. FRANCE RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 49. UK RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 50. UK RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 51. UK RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 52. UK RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 53. ITALY RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 54. ITALY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 55. ITALY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 56. ITALY RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 57. SPAIN RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 58. SPAIN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 59. SPAIN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 60. SPAIN RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 61. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 62. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 63. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 64. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 65. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 66. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 67. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 68. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 69. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 70. JAPAN RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 71. JAPAN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 72. JAPAN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 73. JAPAN RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 74. CHINA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 75. CHINA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 76. CHINA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 77. CHINA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 78. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 79. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 80. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 81. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 82. INDIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 83. INDIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 84. INDIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 85. INDIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 86. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 87. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 88. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 89. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 90. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 91. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 92. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 93. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 94. LAMEA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 95. LAMEA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 96. LAMEA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 97. LAMEA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 98. LAMEA RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 99. BRAZIL RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 100. BRAZIL RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 101. BRAZIL RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 102. BRAZIL RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 103. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 104. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 105. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 106. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 107. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 108. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 109. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 110. SOUTH AFRICA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 111. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 112. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 113. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 114. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 115. CURIUM PHARMA: KEY EXECUTIVES
TABLE 116. CURIUM PHARMA: COMPANY SNAPSHOT
TABLE 117. CURIUM PHARMA: PRODUCT SEGMENTS
TABLE 118. CURIUM PHARMA: PRODUCT PORTFOLIO
TABLE 119. CURIUM PHARMA: KEY STRATERGIES
TABLE 120. CARDINAL HEALTH INC.: KEY EXECUTIVES
TABLE 121. CARDINAL HEALTH INC.: COMPANY SNAPSHOT
TABLE 122. CARDINAL HEALTH INC.: PRODUCT SEGMENTS
TABLE 123. CARDINAL HEALTH INC.: PRODUCT PORTFOLIO
TABLE 124. CARDINAL HEALTH INC.: KEY STRATERGIES
TABLE 125. GENERAL ELECTRIC COMPANY: KEY EXECUTIVES
TABLE 126. GENERAL ELECTRIC COMPANY: COMPANY SNAPSHOT
TABLE 127. GENERAL ELECTRIC COMPANY: PRODUCT SEGMENTS
TABLE 128. GENERAL ELECTRIC COMPANY: PRODUCT PORTFOLIO
TABLE 129. GENERAL ELECTRIC COMPANY: KEY STRATERGIES
TABLE 130. ISO-TEX DIAGNOSTICS, INC: KEY EXECUTIVES
TABLE 131. ISO-TEX DIAGNOSTICS, INC: COMPANY SNAPSHOT
TABLE 132. ISO-TEX DIAGNOSTICS, INC: PRODUCT SEGMENTS
TABLE 133. ISO-TEX DIAGNOSTICS, INC: PRODUCT PORTFOLIO
TABLE 134. LANTHEUS HOLDINGS, INC.: KEY EXECUTIVES
TABLE 135. LANTHEUS HOLDINGS, INC.: COMPANY SNAPSHOT
TABLE 136. LANTHEUS HOLDINGS, INC.: PRODUCT SEGMENTS
TABLE 137. LANTHEUS HOLDINGS, INC.: PRODUCT PORTFOLIO
TABLE 138. LANTHEUS HOLDINGS, INC.: KEY STRATERGIES
TABLE 139. SIEMENS AG: KEY EXECUTIVES
TABLE 140. SIEMENS AG: COMPANY SNAPSHOT
TABLE 141. SIEMENS AG: PRODUCT SEGMENTS
TABLE 142. SIEMENS AG: PRODUCT PORTFOLIO
TABLE 143. JUBILANT PHARMOVA LIMITED: KEY EXECUTIVES
TABLE 144. JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT
TABLE 145. JUBILANT PHARMOVA LIMITED: PRODUCT SEGMENTS
TABLE 146. JUBILANT PHARMOVA LIMITED: SERVICE SEGMENTS
TABLE 147. JUBILANT PHARMOVA LIMITED: PRODUCT PORTFOLIO
TABLE 148. JUBILANT PHARMOVA LIMITED: KEY STRATERGIES
TABLE 149. NOVARTIS AG: KEY EXECUTIVES
TABLE 150. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 151. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 152. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 153. NOVARTIS AG: KEY STRATERGIES
TABLE 154. BAYER AG: KEY EXECUTIVES
TABLE 155. BAYER AG: COMPANY SNAPSHOT
TABLE 156. BAYER AG: PRODUCT SEGMENTS
TABLE 157. BAYER AG: PRODUCT PORTFOLIO
TABLE 158. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 159. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 160. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
TABLE 161. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 162. ELI LILLY AND COMPANY: KEY STRATERGIES
※본 조사보고서 [글로벌 방사성 의약품 시장 (2023-2032) : 테크네튬 99m, 불소 18, 요오드 I, 갈륨 68, 기타] (코드 : ALD23SEP124) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [글로벌 방사성 의약품 시장 (2023-2032) : 테크네튬 99m, 불소 18, 요오드 I, 갈륨 68, 기타] 에 대해서 E메일 문의는 여기를 클릭하세요.
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!